Literaturverzeichnis_neu Literatur Update: September 2025
REVIEWS AND GUIDELINES
ANDEMBRY (garadacimab-gxii)
Beninger P. ANDEMBRY (garadacimab-gxii). Clin Ther. 2025 Sep;47(9):823-824. doi: 10.1016/j.clinthera.2025.07.020. Epub 2025 Aug 20. PMID: 40841306.
Acquired Angioedema as the First Sign of Lymphoproliferative Disorder: Case Report and Review of Literature
Cardenas Rosales JC, Ridwan A, Ruiz-Orasma C, Galeano-Lovera SF, Gil Lopez F, Perusina J, Squire JD, Jiang L, Moustafa MA, Harris DM, Iftikhar S, Munipalli B. Acquired Angioedema as the First Sign of Lymphoproliferative Disorder: Case Report and Review of Literature. J Prim Care Community Health. 2025 Jan-Dec;16:21501319251360500. doi: 10.1177/21501319251360500. Epub 2025 Jul 31. PMID: 40741790; PMCID: PMC12317231.
Acquired Angioedema as the First Sign of Lymphoproliferative Disorder: Case Report and Review of Literature
Cardenas Rosales JC, Ridwan A, Ruiz-Orasma C, Galeano-Lovera SF, Gil Lopez F, Perusina J, Squire JD, Jiang L, Moustafa MA, Harris DM, Iftikhar S, Munipalli B. Acquired Angioedema as the First Sign of Lymphoproliferative Disorder: Case Report and Review of Literature. J Prim Care Community Health. 2025 Jan-Dec;16:21501319251360500. doi: 10.1177/21501319251360500. Epub 2025 Jul 31. PMID: 40741790; PMCID: PMC12317231.
CLINICAL STUDIES
Expanding the Genetic and Clinical Spectrum of Hereditary Angioedema with Normal C1 Inhibitor: Novel Variants and Treatment Insights. Gao H, Zhao Y, Chen S, Zhang Z, Yang F, Chen Z, Wang L, Yang J, He S, Tang C, Zheng S, Guan C, Xu Y, Tang L, Zhang A, Maurer M, Lee D, Ma L, Luo X. Expanding the Genetic and Clinical Spectrum of Hereditary Angioedema with Normal C1 Inhibitor: Novel Variants and Treatment Insights. J Clin Immunol. 2025 Aug 23;45(1):124. doi: 10.1007/s10875-025-01912-z. PMID: 40848077; PMCID: PMC12374894. Reviews and Guidelines
ANDEMBRY (garadacimab-gxii)
Beninger P. ANDEMBRY (garadacimab-gxii). Clin Ther. 2025 Sep;47(9):823-824. doi: 10.1016/j.clinthera.2025.07.020. Epub 2025 Aug 20. PMID: 40841306.
Aktuelle Leitlinien und Konsens-Empfehlungen für die Therapie des HAE
Maurer M et al., The international WAO/EAACI guideline for the management of hereditaryangioedema-The 2021 revision and update. Allergy. 2022 Jan 10
https://pubmed.ncbi.nlm.nih.gov/35006617/
Maurer M et al., Consensus on treatment goals in hereditary angioedema: A global Delphi initiative. J Allergy Clin Immunol. 2021 May 25
https://pubmed.ncbi.nlm.nih.gov/34048855/
Krankheitslast durch HAE und HAE-Management
Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol. 2012 Sep;130(3):692-7. doi: 10.1016/j.jaci.2012.05.055. Epub 2012 Jul 28. PMID: 22841766.
Literatur Update: September 2025
ANDEMBRY (garadacimab-gxii)
Beninger P. ANDEMBRY (garadacimab-gxii). Clin Ther. 2025 Sep;47(9):823-824. doi: 10.1016/j.clinthera.2025.07.020. Epub 2025 Aug 20. PMID: 40841306.
Acquired Angioedema as the First Sign of Lymphoproliferative Disorder: Case Report and Review of Literature
Cardenas Rosales JC, Ridwan A, Ruiz-Orasma C, Galeano-Lovera SF, Gil Lopez F, Perusina J, Squire JD, Jiang L, Moustafa MA, Harris DM, Iftikhar S, Munipalli B. Acquired Angioedema as the First Sign of Lymphoproliferative Disorder: Case Report and Review of Literature. J Prim Care Community Health. 2025 Jan-Dec;16:21501319251360500. doi: 10.1177/21501319251360500. Epub 2025 Jul 31. PMID: 40741790; PMCID: PMC12317231.
Acquired Angioedema as the First Sign of Lymphoproliferative Disorder: Case Report and Review of Literature
Cardenas Rosales JC, Ridwan A, Ruiz-Orasma C, Galeano-Lovera SF, Gil Lopez F, Perusina J, Squire JD, Jiang L, Moustafa MA, Harris DM, Iftikhar S, Munipalli B. Acquired Angioedema as the First Sign of Lymphoproliferative Disorder: Case Report and Review of Literature. J Prim Care Community Health. 2025 Jan-Dec;16:21501319251360500. doi: 10.1177/21501319251360500. Epub 2025 Jul 31. PMID: 40741790; PMCID: PMC12317231.
CLINICAL STUDIES
Expanding the Genetic and Clinical Spectrum of Hereditary Angioedema with Normal C1 Inhibitor: Novel Variants and Treatment Insights. Gao H, Zhao Y, Chen S, Zhang Z, Yang F, Chen Z, Wang L, Yang J, He S, Tang C, Zheng S, Guan C, Xu Y, Tang L, Zhang A, Maurer M, Lee D, Ma L, Luo X. Expanding the Genetic and Clinical Spectrum of Hereditary Angioedema with Normal C1 Inhibitor: Novel Variants and Treatment Insights. J Clin Immunol. 2025 Aug 23;45(1):124. doi: 10.1007/s10875-025-01912-z. PMID: 40848077; PMCID: PMC12374894.
Reviews and Guidelines
ANDEMBRY (garadacimab-gxii)
Beninger P. ANDEMBRY (garadacimab-gxii). Clin Ther. 2025 Sep;47(9):823-824. doi: 10.1016/j.clinthera.2025.07.020. Epub 2025 Aug 20. PMID: 40841306.
Aktuelle Leitlinien und Konsens-Empfehlungen für die Therapie des HAE
Maurer M et al., The international WAO/EAACI guideline for the management of hereditaryangioedema-The 2021 revision and update. Allergy. 2022 Jan 10
https://pubmed.ncbi.nlm.nih.gov/35006617/
Maurer M et al., Consensus on treatment goals in hereditary angioedema: A global Delphi initiative. J Allergy Clin Immunol. 2021 May 25
https://pubmed.ncbi.nlm.nih.gov/34048855/
Krankheitslast durch HAE und HAE-Management
Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol. 2012 Sep;130(3):692-7. doi: 10.1016/j.jaci.2012.05.055. Epub 2012 Jul 28. PMID: 22841766.